查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466142

药品製造市场：按配方、药物开发类型、途径、药物、年龄层、分销管道、治疗领域 - 全球预测 2024-2030

Pharmaceutical Manufacturing Market by Formulation (Capsules, Injectable, Powders), Drug Development Type (In-House, Outsource), Route of Administration, Drugs, Age Group, Distribution Channel, Therapy Area - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年药品製造市场规模为6,206.8亿美元，预估2024年将达6,724.4亿美元，2030年将达11.1017亿美元，复合年增长率为8.66%。

药品製造包括人类药品和药品的研究、开发、生产、行销和分销。这些产品旨在用于各种医疗保健环境中的疾病预防、诊断、治疗和管理。主要最终使用者包括急性或慢性病患者、医疗保健专业人员、临床试验研究人员、保险公司和监管机构。人口老化加剧、慢性病盛行率高，以及针对世界各地未满足的医疗需求对先进药物的需求增加，正在影响製药业的成长。政府增加的资金也支持医疗领域的研发活动，并使製药公司能够开发新药。然而，国家当局严格的监管要求和漫长的临床试验过程给新药製造商造成了进入障碍。

主要市场统计
基准年[2023] 6206.8亿美元
预测年份 [2024] 6724.4亿美元
预测年份 [2030] 11,101.70亿美元
复合年增长率（%） 8.66%

此外，来自学名药的竞争日益激烈以及维持强大的供应链已成为主要挑战。此外，药物开发过程中的技术进步和对个人化医疗日益增长的兴趣正在为市场成长创造持续的机会。此外，引进数位技术来优化研发流程也提高了药物开发效率。

配方：投资激增，支持注射配方的稳健研究和开发

胶囊因其易于吞嚥和剂量准确而受到青睐。胶囊适用于即时释放和持续释放製剂。此註射製剂绕过胃肠道吸收屏障，因此具有快速起效和高生物利用度。这些通常用于救命药物、疫苗和生物製药。粉末製剂非常适合吞嚥锭剂或胶囊有困难的患者，并且可以根据需要重新配製为方便的口服混悬剂或外用製剂。喷雾剂适合局部给药，例如鼻腔或脸颊给药。它吸收迅速，生物有效性度高，非常适合紧急给药。混悬剂给药弹性，适合吞嚥固态有困难的儿童及老年患者。由于其便携性、易于製造和成本效益，锭剂仍然是最受欢迎的剂型。每种剂型根据给药途径、起效时间、生物有效性、剂量准确性、易用性和患者偏好等因素满足特定患者的需求。

药品开发类型：委託药品生产因成本效益而增加

内部药物开发是指製药公司在内部进行所有研发、临床试验、监管合规、生产、行销和分销。选择这种方法的公司通常拥有全面的研发设施和熟练的人员，可以在受控环境中管理药物开发过程的各个方面。外包涉及与外部组织（例如委託研究或製造组织）合作，以促进药物开发过程的各个阶段。外包合作伙伴可以提供从临床前测试到上市后监测的广泛服务。当公司缺乏特定药物开发阶段所需的设施或专业知识时，他们更喜欢外包。此外，外包可以利用第三方供应商的专业知识和资源来降低成本并加快上市时间。

给药途径: 由于慢性病的增加，活性化了肠外给药的研究和开发

以吸入为基础的药物传递主要用于治疗呼吸系统疾病，例如气喘、囊肿纤维化和慢性阻塞性肺病。由于有针对性的肺部沉积，该途径可以更快起效并提高安全性。口服给药是最优选的途径，因为它易于给药、患者依从性、剂型的弹性和成本效益。肠外给药包括静脉（IV）、肌肉内（IM）和皮下（SC）注射，起效快，生物利用度为100%，非常适合紧急治疗，是需要长期护理的慢性疾病的理想选择。例如糖尿病和癌症。局部给药特别适用于皮肤炎、干癣和痤疮等皮肤病的局部治疗，以及涂布乳霜、凝胶和贴片直接涂抹到受影响区域来缓解疼痛。

药物：非处方药趋势

非处方药 (OTC) 对于为消费者提供常见疾病的有效治疗方法至关重要。乙酰胺酚是一种广泛使用的止痛药，可缓解轻度至中度疼痛，并有效缓解多种情况下的发烧，包括头痛、月经来潮、背痛、牙痛和关节炎。次水杨酸铋是一种抗酸剂和止泻药，用于治疗常见的胃肠道疾病，如消化不良、胃灼热、噁心和腹泻。Dextromethorphan(DXM) 是一种止咳药，可暂时缓解大脑髓质区域的咳嗽反射。Hydrocortisone乳膏是一种外用皮质类固醇，用于透过减轻发炎和搔痒来治疗湿疹、皮肤炎和昆虫叮咬等皮肤病。Ibuprofen通常用于缓解头痛、牙痛、月经痛和肌肉骨骼损伤。假麻黄碱是一种鼻减充血剂，存在于许多感冒药中，可透过缩小鼻道血管、减少肿胀和黏液积聚来缓解鼻塞。处方药在由药剂师配发之前必须得到医疗保健专业人员的核准。这些药物通常用于治疗较严重或慢性的疾病，需要专门的医疗介入以确保安全使用和最佳治疗结果。对乙酰胺酚加氢可酮用于治疗中度至重度疼痛。氨氯地平具有舒张血管和改善血流的作用，常用于治疗高血压和心绞痛。Lisinopril可扩张血管、降低血压，用于治疗高血压。Metformin用于治疗第 2 型糖尿病，以及饮食改变和运动计画。Simvastatin可降低胆固醇水平并降低心肌梗塞等心血管疾病的风险。

年龄层：非常需要治疗老年人疾病的製剂

成年人需要药物来控制高血压、糖尿病、心血管疾病和精神疾病等慢性疾病。最近的趋势表明，对针对个人遗传组成、生活方式因素和环境影响的个人化医疗的需求日益增长。对于儿童和青少年来说，由于学校强制免疫以及预防麻疹和水痘等儿童疾病，疫苗发挥重要作用。此外，为了确保儿童的用药遵从性，需要考虑剂量准确性和偏好的儿童用製剂。人口老化面临失智症、关节炎和骨质疏鬆等慢性疾病。药物治疗必须适合年龄，并仔细考虑药物交互作用、副作用以及肾功能和肝功能的剂量调整。不同年龄层的药品生产环境在药物治疗需求和偏好上有所不同。成人药物治疗着重于透过个人化方法管理慢性疾病，而儿童用製剂则着重于疫苗开发和依从性考量。在老年族群中，应特别注意由于老龄化相关的生理变化而导致的药物交互作用和剂量调整。

通路：药品非零售通路的普及

非零售分销管道主要针对医院、诊所、政府机构、疗养院和其他医疗机构。在这一领域，设施买家大量购买药品，以满足在这些设施内接受治疗的患者的医疗需求。非零售分销是首选，因为所需的特殊药物无法透过零售通路轻易取得或在经济上不可行。零售分销透过线上和线下药局、超级市场、药局和通讯服务迎合个人消费者。客户依靠零售分销来快速、轻鬆地采购非处方药 (OTC)、处方药和其他医疗产品。此零售通路旨在为消费者提供广泛的选择、有竞争力的价格以及个人化服务，例如药物咨询和健康检查。非零售部门专注于需要大量订购特殊药品的机构投资者，而零售部门则迎合寻求便利、可用性和多样化产品的个人消费者。

治疗领域：开发新癌症治疗方法的技术创新浪潮

过敏性疾病的全球流行增加了对过敏治疗和药物的需求。由于人口迅速老化和不健康的生活方式导致心臟病的流行，对心血管治疗的需求正在增加。坏血病、皮肤炎、皮肤感染疾病等皮肤病的增加需要高效率的药物。由于糖尿病发生率不断增加，需要有效的治疗方法。胃肠道疾病的增加需要胃肠道治疗和药物的进步。感染疾病在世界各地广泛传播，需要不断开发疫苗和抗病毒药物。由于神经系统疾病的负担日益增加，迫切需要改进药物和治疗方法。癌症仍然是死亡和受伤的主要原因，推动了对创新癌症治疗的需求。人口老化正在增加眼科疾病的盛行率并增加对眼部护理的需求。慢性疼痛是全球性的负担，需要有效的止痛药和非类固醇消炎剂。精神疾病影响全世界数百万人，需要在精神卫生保健上取得治疗方法突破。慢性呼吸道疾病正在影响对新型肺部治疗的需求。肾臟疾病呈上升趋势，需要创新的肾臟治疗方法。气喘和慢性阻塞性肺病病例需要呼吸治疗领域的进步。

区域洞察

美洲由于强大的研发能力、大型製药企业的存在以及有利的政府政策，在全球医药市场中占有重要地位。我们在美国拥有一家经 FDA 批准的生产工厂，专注于生产生技药品和复杂的学名药。德国、法国、瑞士和英国等欧洲国家都是拥有创新製造技术的先进製药公司的所在地。这些製造商大力投资创新药物疗法，同时遵守欧洲药品管理局所製定的严格监管标准。亚太倡议旨在促进国内生产和创新，鼓励对研发和先进製造技术的投资。这项政策导致製药公司新专利申请量迅速增加。此外，亚太地区私营和公共部门对医疗保健的投资增加刺激了药品製造业。

FPNV定位矩阵

FPNV定位矩阵对于评估药品製造市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对药品製造市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、碎片化主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的智力见解。

本报告解决了以下关键问题：

1.医药製造市场的市场规模与预测是多少？

2.在药品製造市场的预测期内，我们应该考虑投资哪些产品和应用？

3.药品製造市场的技术趋势和法规结构是什么？

4.医药製造市场主要厂商的市场占有率为何？

5.进入药品製造市场的适当型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球对疫苗和药物的需求增加
      • 医药品研究开发费用增加
      • 老年人口增加和慢性病发生率增加
    • 抑制因素
      • 与药品製造相关的高成本和复杂性
    • 机会
      • 加大医药製造领域投资金筹措力度
      • 新药品製造技术的出现
    • 任务
      • 政府对製药公司的严格监管
  • 市场区隔分析
    • 配方：投资激增以支持注射剂的强劲研发
    • 药物开发类型：由于成本效益，外包药物生产的使用增加
    • 给药途径：随着慢性病盛行率的不断增加，肠外给药的研发活动不断增加。
    • 药物：成药) 的趋势
    • 年龄层：非常需要药物处方来治疗老年疾病
    • 分销通路：药品非零售通路的渗透
    • 治疗领域：开发新肿瘤治疗方法的创新浪潮
  • 市场趋势分析
    • 美洲医药产业蓬勃发展，医药投资与出口快速成长
    • 政府对亚太地区国内製药製造业的支持措施与投资
    • 主要製药商正在向欧洲、中东和非洲扩张，重点是新药的研发。
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化
    • 2022年最畅销处方药和非成药排行榜

第六章 药品製造市场：依配方分类

  • 介绍
  • 胶囊
  • 注射
  • 粉末
  • 喷
  • 暂停
  • 锭剂

第七章药品製造市场：依药物开发类型

  • 介绍
  • 公司内部
  • 外包

第八章 药品製造市场：依管理途径

  • 介绍
  • 吸入
  • 口服
  • 胃肠外的
  • 局部的

第九章药品製造市场：依药品分类

  • 介绍
  • 成药
  • 处方药

第10章药品製造市场：依年龄组别

  • 介绍
  • 成人
  • 婴儿和青少年
  • 老年人

第十一章药品製造市场：依通路分类

  • 介绍
  • 非零售
  • 零售

第十二章药品製造市场：依治疗领域

  • 介绍
  • 过敏
  • 心血管疾病
  • 皮肤科
  • 糖尿病
  • 胃肠病学
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 眼科
  • 疼痛管理
  • 心理保健
  • 肺
  • 肾臟疾病
  • 呼吸系统疾病

第十三章美洲药品製造市场：按地区

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第14章亚太药品製造市场：按地区

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲药品製造市场：按地区

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析

第十七章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-22146147675F

[181 Pages Report] The Pharmaceutical Manufacturing Market size was estimated at USD 620.68 billion in 2023 and expected to reach USD 672.44 billion in 2024, at a CAGR 8.66% to reach USD 1,110.17 billion by 2030.

Pharmaceutical manufacturing comprises research, development, production, marketing, and distribution of drugs and medicinal products for human use. These products target disease prevention, diagnosis, treatment, and management in various healthcare settings. Key end-users include patients with acute or chronic illnesses, healthcare professionals, clinical trial researchers, insurance companies, and regulatory agencies. Rising aging populations with a higher prevalence of chronic diseases across the globe and increasing need for advanced medicines targeting unmet medical needs influence the growth in the pharmaceutical sector. In addition, rising government funding supports research and development activities in the healthcare sector, allowing new drug development for pharmaceutical companies. However, stringent regulatory requirements imposed by national authorities and the lengthy clinical trial processes create barriers to entry for new pharmaceutical manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 620.68 billion
Estimated Year [2024] USD 672.44 billion
Forecast Year [2030] USD 1,110.17 billion
CAGR (%) 8.66%

Moreover, increasing competition from generics and biosimilars and maintaining a robust supply chain pose significant challenges. Furthermore, the technological advancements in drug development processes and a growing focus on personalized medicine create sustainable opportunities for market growth. Also, embracing digital technologies to optimize R&D processes, enhancing the drug development efficiency

Formulation: Surging investment to support robust research and development of injectable formulations

Capsules are preferred for their ease of swallowing and accurate dosing capabilities. They are suitable for both immediate-release and extended-release formulations. Injectable formulations offer rapid onset of action and high bioavailability as they bypass gastrointestinal absorption barriers. These are commonly used for life-saving medications, vaccines, and biopharmaceutical products. Powders are ideal for patients with difficulty swallowing tablets and capsules; they can be reconstituted into convenient oral suspensions and topical applications when needed. Sprays are preferred for localized drug delivery, such as nasal and buccal administration. They offer rapid absorption and high bioavailability, making them ideal for emergency medications. Suspensions provide flexibility in dosing and are suitable for pediatric and senior patients who have difficulty swallowing solid dosage forms. Tablets remain the most popular dosage form due to their portability, ease of manufacturing, and cost-effectiveness. Each formulation type serves specific patient needs based on factors such as administration route, onset of action, bioavailability, dosing accuracy, ease of use, and patient preferences.

Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness

In-house drug development entails a pharmaceutical company conducting all research and development (R&D), clinical trials, regulatory compliance, production, marketing, and distribution within its organization. Companies that choose this approach often have comprehensive R&D facilities and skilled personnel to manage all aspects of the drug development process in a controlled environment. Outsourcing involves partnering with external organizations, such as contract research and manufacturing organizations, to facilitate various stages of the drug development process. Outsourcing partners may offer services ranging from preclinical studies to post-marketing surveillance. Companies prefer outsourcing if they lack the necessary facilities and expertise for specific drug development phases. Additionally, outsourcing can help control costs and reduce time-to-market by leveraging third-party vendors' specialized knowledge and resources.

Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease

Inhalation-based drug delivery is primarily preferred for treating respiratory disorders, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease. This route offers a rapid onset of action and improved safety due to targeted lung deposition. Oral administration is the most favored route due to its ease of administration, patient compliance, flexibility in dosage forms, and cost-effectiveness. Parenteral drug delivery includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections, offering rapid onset of action with 100% bioavailability, making it ideal for emergency treatments and chronic illnesses requiring long-term care, such as diabetes and cancer. Topical drug administration is particularly suitable for localized treatment of skin disorders such as dermatitis, psoriasis, and acne, and pain relief by applying creams, gels, and patches directly onto the affected area.

Drugs: Inclination toward Over-the-counter (OTC) drugs

Over-the-counter (OTC) drugs are vital in providing consumers with accessible and effective treatments for common ailments. Acetaminophen is a widely used analgesic and effectively relieves mild to moderate pain and alleviates fever in various conditions such as headaches, menstrual cramps, backaches, dental pain, and arthritis. Bismuth subsalicylate is an antacid and anti-diarrheal medication used to treat common gastrointestinal issues such as indigestion, heartburn, nausea, and diarrhea. Dextromethorphan (DXM) is a cough suppressant drug that temporarily relieves the cough reflex in the brain's medulla oblongata region. Hydrocortisone creams are topical corticosteroids designed to treat skin conditions, including eczema, dermatitis, and insect bites, by reducing inflammation and itching. Ibuprofen is commonly used to relieve headaches, dental pain, menstrual cramps, or musculoskeletal injuries. Pseudoephedrine is a nasal decongestant found in many cold medications and relieves congestion by narrowing blood vessels in the nasal passages and reducing swelling and mucus buildup. Prescription medicines require authorization from a healthcare professional before being dispensed by a pharmacist. These medications are often prescribed for more severe or chronic conditions where specialized medical intervention is necessary to ensure safe use and optimal therapeutic outcomes. Acetaminophen Plus Hydrocodone is used to manage moderate to severe pain. Amlodipine works by relaxing blood vessels and improving blood flow and is commonly prescribed for hypertension and angina. Lisinopril expands blood vessels, reduces blood pressure, and is prescribed for hypertension treatment. Metformin is prescribed for type 2 diabetes management alongside dietary changes and exercise programs. Simvastatin lowers cholesterol levels to reduce the risk of heart strokes and other cardiovascular problems.

Age Group: Significant need for drug formulations to treat geriatric medical conditions

Adults require medications for managing chronic conditions such as hypertension, diabetes, cardiovascular diseases, or mental health disorders. Recent trends indicate a growing need for personalized medicine that caters to individual genetic makeup, lifestyle factors, and environmental influences. For children & adolescents, vaccines play a vital role due to school immunization requirements and protection against childhood diseases, including measles or chickenpox. Additionally, there is a need for pediatric formulations that consider dosage accuracy and palatability to ensure medication adherence among children. The geriatric population faces chronic conditions such as dementia, arthritis, or osteoporosis. Medications must be age-appropriate with careful consideration of drug-drug interactions, side effects, and dosing adjustments based on renal and hepatic function. The pharmaceutical manufacturing landscape differs across various age groups regarding medication needs and preferences. While adult medications focus on managing chronic conditions with personalized approaches, pediatric formulations emphasize vaccine development and adherence considerations. Geriatric populations require special attention to drug interactions and dosage adjustments due to age-related physiological changes.

Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals

Non-retail distribution channels primarily cater to hospitals, clinics, government agencies, long-term care facilities, and other healthcare institutions. This segment involves bulk purchasing of pharmaceutical products by institutional buyers to meet the healthcare needs of patients receiving treatment within these establishments. The preference for non-retail distribution arises from the need for specialized medications that may not be readily available or economically viable through retail channels. Retail distribution caters to individual consumers through pharmacies both online and offline), supermarkets, drugstores, and mail-order services. Customers depend on retail distribution for over-the-counter (OTC) medications, prescription drugs, and other healthcare products that can be quickly and conveniently procured. Retail channels aim to offer consumers a wide range of options, competitive pricing, and personalized services such as medication counseling or health screenings. Non-retail focuses on institutional buyers that require bulk orders of specialized medications, while retail caters to individual consumers seeking convenience, accessibility, and a diverse product range.

Therapy Area: Wave of innovations toward development of new oncology treatment modalities

The increasing prevalence of allergic conditions worldwide drives the need for allergy treatment and drugs. The surge in aging populations and unhealthy lifestyles contributing to heart disease prevalence raises the need for cardiovascular therapies. The rise in a number of dermatology conditions, such as scurvy, dermatitis, and skin infections, necessitates efficient drugs. The rising diabetes epidemic creates a substantial need for effective therapies. Growth in gastrointestinal diseases necessitates advancements in gastroenterology treatments and medicines. Infectious diseases persist globally, requiring continuous vaccine and antiviral development. The rising burden of neurological disorders contributes to a significant need for improved drugs and therapeutics. Cancer remains a leading cause of casualties, driving the need for innovative oncology therapies. Aging populations contribute to increased eye disease prevalence and necessitate ophthalmic treatments. The global burden of chronic pain propels the need for effective analgesics or nonsteroidal anti-inflammatory drugs. Mental health disorders affect millions globally and require therapeutic breakthroughs within psychiatry. Chronic respiratory diseases influence the need for novel pulmonary treatments. The increasing prevalence of kidney disease requires innovative renal therapies. Cases of asthma and COPD necessitate advancements within the respiratory therapy area segment.

Regional Insights

The Americas hold a significant position in the global pharmaceutical market, attributed to its strong research & development (R&D) capabilities, presence of leading pharmaceutical companies, and favorable government policies. The United States has FDA-approved manufacturing facilities focusing on producing biologics and complex generics. European countries, including Germany, France, Switzerland, and the United Kingdom, have advanced pharmaceutical companies with innovative production technologies. These manufacturers have been investing heavily in innovative drug therapies while complying with stringent regulatory standards set by the European Medicines Agency. The Asia Pacific countries initiative aims to boost domestic production and innovation, encouraging investment in R&D and advanced manufacturing technologies. Their policies have led to a surge in new patents filed by pharmaceutical companies. Moreover, the rising investments in healthcare by the private and public sectors in the APAC region fueled the pharmaceutical manufacturing industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmaceutical Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmaceutical Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Actiza Pharmaceutical Pvt. Ltd., Advent Pharma Ltd., Aenova Group GmbH, Amgen Inc., AstraZeneca PLC, Asymchem, Inc., Azurity Pharmaceuticals, Inc., Bayer AG, Biocon Limited, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Famar Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lonza Group AG, Lupin Limited, McKesson Corporation, Merck KGaA, Moderna, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Veranova, L.P., and Zeon Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Formulation
    • Capsules
    • Injectable
    • Powders
    • Sprays
    • Suspensions
    • Tablets
  • Drug Development Type
    • In-House
    • Outsource
  • Route of Administration
    • Inhalations
    • Oral
    • Parenteral
    • Topical
  • Drugs
    • Over-the-Counter (OTC) Medicines
    • Prescription Medicines
  • Age Group
    • Adults
    • Children & Adolescents
    • Geriatric
  • Distribution Channel
    • Non-Retail
    • Retail
  • Therapy Area
    • Allergy
    • Cardiovascular Diseases
    • Dermatology
    • Diabetes
    • Gastroenterology
    • Infectious Disease
    • Neurology
    • Oncology
    • Ophthalmology
    • Pain Management
    • Psychiatry
    • Pulmonary
    • Renal Disease
    • Respiratory Diseases
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmaceutical Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmaceutical Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Pharmaceutical Manufacturing Market?

4. What is the market share of the leading vendors in the Pharmaceutical Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Pharmaceutical Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in global demand for vaccines and drugs
      • 5.1.1.2. Growing pharmaceutical R&D spending
      • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complexities associated with the pharma production
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
      • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for pharmaceutical companies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
    • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
    • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
    • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
    • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
    • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
    • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
  • 5.3. Market Trend Analysis
    • 5.3.1. Flourishing pharmaceutical industry and burgeoning pharmaceutical investment & exports in the Americas
    • 5.3.2. Supportive government initiatives and investments for domestic pharmaceutical manufacturing in the Asia-Pacific
    • 5.3.3. Emphasis on R&D of novel drugs and presence of significant pharmaceutical manufacturers in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis
  • 5.8. Client Customization
    • 5.8.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injectable
  • 6.4. Powders
  • 6.5. Sprays
  • 6.6. Suspensions
  • 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

  • 7.1. Introduction
  • 7.2. In-House
  • 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Oral
  • 8.4. Parenteral
  • 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

  • 9.1. Introduction
  • 9.2. Over-the-Counter (OTC) Medicines
  • 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Children & Adolescents
  • 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Non-Retail
  • 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

  • 12.1. Introduction
  • 12.2. Allergy
  • 12.3. Cardiovascular Diseases
  • 12.4. Dermatology
  • 12.5. Diabetes
  • 12.6. Gastroenterology
  • 12.7. Infectious Disease
  • 12.8. Neurology
  • 12.9. Oncology
  • 12.10. Ophthalmology
  • 12.11. Pain Management
  • 12.12. Psychiatry
  • 12.13. Pulmonary
  • 12.14. Renal Disease
  • 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
    • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
    • 16.3.3. Novo, Torrent may Widen Tie-Up
    • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
    • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
    • 16.3.6. Aenova and Galvita Enter Strategic Partnership
    • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
    • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
    • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
    • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

17. Competitive Portfolio

  • 17.1. Key Company Profiles
  • 17.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 24. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 30. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 94. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 95. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 96. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 97. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 100. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 101. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 112. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 113. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 116. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 126. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 127. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 130. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 192. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 200. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 205. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 206. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 207. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 212. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 213. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 214. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 215. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 218. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 219. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 220. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 221. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 228. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 229. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 232. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 233. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 234. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 235. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 238. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 239. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 240. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 241. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 242. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 243. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 246. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 247. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 248. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 249. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 254. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 255. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 256. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 257. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 260. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 261. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 262. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 263. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 270. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 271. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 274. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 276. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 288. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 289. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 290. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 291. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 296. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 297. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 298. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 299. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 300. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 301. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 302. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 304. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 305. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 310. SOUTH KOREA PHARMACEUTICAL MA